
Applied and Translational Neurogenomics of FTLD and Related Disorders

Group Leader: Prof. Dr. Rosa Rademakers

What is FTLD?

FTLD is highly heterogeneous

Frontotemporal Lobar Degeneration (FTLD) is the second most common young-onset dementia (onset <65 years old). FTLD patients present behavioral, language, memory, and movement dysfunctions.




What is our research focus?




BIOINFORMATICS (75%)

Genetics & Epigenetics

Employing short and long-read whole genome sequencing technologies, we aim to unravel underlying (epi)genetic risk for FTLD, causal genes for genetically unexplained patients and genetic modifiers of disease mechanisms.







Transcriptomics & Proteomics

We use **single-nuclei transcriptomics** to map cell-type-specific gene expression changes in FTLD. Proteomic analyses are used to investigate protein-level alterations in FTLD. With these approaches, we aim to identify disrupted molecular pathways and key modulators of the disease mechanism.

No experience with bioinformatics or programming needed

Bring your curiosity and a drive to learn — that's all it takes!






BENCHWORK (25%)



iPSC-derived cortical neuronal models


We use iPSC-derived models from patients and healthy individuals to understand disease mechanisms. We also use genomic engineering (CRISPR-Cas9, TALENs) to knockout and overexpress genes of interest (obtained from our genetics studies) and investigate them in a human model.



Functional assays

We analyze the phenotypes in our models using several functional assays, including proteomics and transcriptomics, organelle trafficking, neuron-microglia co-cultures, neuronal xenografts, and confocal imaging.





Any questions?: thesis_rr@uantwerpen.be





Apply now via the QR code or link below!

